NCT06258915View on ClinicalTrials.gov

Treatment FOr Corticosteroid Dependent UveitiS

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

November 1, 2027

Conditions
Non Infectious Uveitis
Interventions
DRUG

Adalimumab

Adalimumab (80mg at day 0, then 40mg/14 days from W1 to W35 subcutaneously)

DRUG

Mycophenolate Mofetil

2 g/day orally for 36 weeks

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER